We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of BAX 888 in Male Adults With Severe Hemophilia A

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03370172
Recruitment Status : Active, not recruiting
First Posted : December 12, 2017
Last Update Posted : November 26, 2021
Sponsor:
Collaborators:
Baxalta Innovations GmbH, now part of Shire
Takeda Development Center Americas, Inc.
Information provided by (Responsible Party):
Takeda ( Baxalta now part of Shire )

Tracking Information
First Submitted Date  ICMJE November 22, 2017
First Posted Date  ICMJE December 12, 2017
Last Update Posted Date November 26, 2021
Actual Study Start Date  ICMJE March 31, 2018
Estimated Primary Completion Date July 8, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 20, 2021)
Number of Participants With BAX 888-Related Adverse Events (AEs) [ Time Frame: From study drug administration to 5 Years ]
An AE is defined as any untoward medical occurrence in a participant administered an investigational product (IP) that does not necessarily have a causal relationship with the treatment. A Serious adverse event (SAE) is an AE resulting in any of the following outcomes: death; life-threatening event; required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. AEs include both serious and non-serious adverse events including development of FVIII inhibitory antibodies, clinically significant changes in standard laboratory parameters, physical exam, and vital signs.
Original Primary Outcome Measures  ICMJE
 (submitted: December 6, 2017)
Incidence of BAX 888-related adverse events (AEs) [ Time Frame: Throughout the study period of approximately 3 years per participant. ]
Includes serious or non-serious adverse events
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 20, 2021)
  • Change from Baseline in Circulating Plasma FVIII Activity Level [ Time Frame: Baseline, up to approximately 5 years per participant ]
    Change from baseline in circulating plasma FVIII activity level, based on one-stage clotting assay will be assessed.
  • Change from Baseline in Circulating Plasma FVIII Antigen Level [ Time Frame: Baseline, up to approximately 5 years per participant ]
    Change from baseline in circulating plasma FVIII antigen (protein) levels will be assessed.
  • Annualized Bleed Rate (ABR) [ Time Frame: Up to 5 years per participant ]
    ABR in comparison to before gene transfer will be assessed. A bleed is defined as subjective or objective evidence of bleeding which may or may not require treatment with FVIII. ABR will be calculated as (number of bleeding episodes/observed treatment period in days)*365.25.
  • Percentage of Participants With a Redaction Consumption of Exogenous FVIII [ Time Frame: Historical data from 12 months prior to study enrollment and 5 years post-infusion ]
    The percentage of participants with a reduction in exogenous FVIII consumption from 12 months prior to study enrollment and up to 5 years post-infusion compared to the historical consumption (consumption of exogenous FVIII during the 12 month period prior to BAX 888 infusion).
  • Number of Participants Develop Inhibitory Antibodies to FVIII [ Time Frame: Up to 5 years per participant ]
    Number of participants develop inhibitory antibodies to FVIII will be assessed.
  • Number of Participants Develop Total Binding Antibodies to FVIII [ Time Frame: Up to 5 years per participant ]
    Number of participants develop total binding antibodies to FVIII (Immunoglobulin G [IgG], Immunoglobulin M [IgM]) and antibody titers will be assessed.
  • Number of Participants With Humoral and Cell-Mediated Immune Response to AAV8 and FVIII Proteins [ Time Frame: Up to 5 years per participant ]
    Number of participants with humoral (antibody-mediated) and cell-mediated immune response to adeno-associated virus (AAV8) (the vector), FVIII protein and antibody titers will be assessed.
  • Surveillance of AAV8 Genome Shedding [ Time Frame: Until 2 consecutive measurements are negative or up to 5 years, whichever is sooner ]
    Surveillance of AAV8 genome shedding in blood, saliva, semen, urine and stool will be assessed.
Original Secondary Outcome Measures  ICMJE
 (submitted: December 6, 2017)
  • Median plasma Factor VIII (FVIII) activity level [ Time Frame: From screening visit to last study visit, at approximately 40 visits (screening & study visits), up to approximately 3 years per participant ]
    Circulating plasma FVIII activity level, based on one-stage clotting assay
  • Median plasma Factor VIII (FVIII) antigen level [ Time Frame: From screening visit to last study visit, at approximately 40 visits (screening & study visits), up to approximately 3 years per participant ]
    Circulating plasma FVIII antigen (protein) level in the plasma
  • Annualized bleed rate (ABR) [ Time Frame: Throughout the study period of approximately 3 years per participant. ]
    Annualized bleed rate (ABR) in comparison to before gene transfer
  • Consumption of exogenous Factor VIII (FVIII) [ Time Frame: Historical data from 12 months prior to study enrollment; and 12 months post-infusion and 3 years post-infusion. ]
    The percentage of participants with a reduction in exogenous FVIII consumption 12 months post-infusion and 3 years post-infusion compared to the historical consumption (consumption of exogenous FVIII during the 12 month period prior to BAX 888 infusion)
  • Number of participants with inhibitory antibodies to FVIII [ Time Frame: Throughout the study period of approximately 3 years per participant. ]
    Development of inhibitory antibodies to FVIII (Nijmegen assay).
  • Number of participants with total binding antibodies to FVIII [ Time Frame: Throughout the study period of approximately 3 years per participant. ]
    Development of total binding antibodies to FVIII (IgG and IgM).
  • Number of participants with humoral and cell-mediated immune response to AAV8 and FVIII proteins. [ Time Frame: Throughout the study period of approximately 3 years per participant. ]
    Humoral (antibody-mediated) and cell-mediated immune response to adeno-associated virus (AAV8) (the vector) and Factor VIII (FVIII) proteins.
  • Surveillance of AAV8 genome shedding [ Time Frame: Throughout the study period of approximately 3 years per participant. ]
    Surveillance of adeno-associated virus (AAV8) genome shedding in blood, saliva, semen, urine and stool
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study of BAX 888 in Male Adults With Severe Hemophilia A
Official Title  ICMJE A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion
Brief Summary

The main aim of this study is to check if there are side effects from BAX 888 and to determine the dose of BAX 888 for treating severe hemophilia A in male adults.

Participants will receive one infusion with BAX 888 at the hemophilia treatment center. During the study, participants will visit their study clinic multiple times.

Detailed Description

This study consists of 3 cohorts. Participants will be assigned to 1 of 3 dose cohorts with a minimum of 24 hours between dosing of each participant. Initially, 2 participants will be dosed in a cohort, with up to a total of 5 participants if the cohort is expanded based on safety and activity levels data.

Dose escalation: After dosing first 2 participants in cohort 1 the decision will be made on the following: If week 4 FVIII activity levels of both participants are less than (<) 2%, then dose escalation to cohort 2 will be triggered with no further dosing in cohort 1. If FVIII activity levels >=2% are observed in at least 1 participant among the 2 participants the decision to escalate dose or expand the cohort with dosing of additional participants will be based on all available data through Week 14.

Dose expansion: After dose escalation and administration of BAX 888 to the first 2 participants in 3 cohorts: If sustained Week 14 FVIII activity levels are >=30% are not achieved in both participants (first 2 participants in cohorts 1 and 2) then escalation to immediate next cohort will be triggered after Data Monitoring Committee (DMC) review of all available safety and FVIII activity levels data. For cohort 3 dosing of additional participants will be paused until further review of available data. If sustained Week 14 FVIII levels are >=30% in at least 1 of the 2 participants (first 2 participant in cohort 1, 2, 3) then expansion of cohorts 1, 2 (with up to 5 participants), 3 (with up to 3 additional participants) will be initiated with dosing or study could be completed with no further dosing.

23 APRIL 2020: Enrollment of new patients into this study has been paused due to the COVID-19 situation. The duration of this pause is dependent on the leveling and control of the COVID-19 pandemic.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE Hemophilia A
Intervention  ICMJE Drug: BAX 888
Participants will receive a single peripheral IV infusion of BAX 888 in Cohort 1, 2, 3 on Day 0.
Other Names:
  • Adeno-associated virus serotype 8 (AAV8) vector expressing B-domain deleted Factor VIII (BDD-FVIII)
  • BAX888
Study Arms  ICMJE
  • Experimental: Cohort 1
    Cohort 1 participants will receive a single peripheral intravenous (IV) infusion of BAX 888 at a dose of 2.0*10^12 capsid particles per kilogram (cp/kg) on the day of dosing (Day 0).
    Intervention: Drug: BAX 888
  • Experimental: Cohort 2
    Cohort 2 participants will receive a single peripheral IV infusion of BAX 888 at a dose of 6.0*10^12 cp/kg on the day of dosing (Day 0).
    Intervention: Drug: BAX 888
  • Experimental: Cohort 3
    Cohort 3 participants will receive a single peripheral IV infusion of BAX 888 at a dose of 1.2*10^13 cp/kg on the day of dosing (Day 0).
    Intervention: Drug: BAX 888
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: November 21, 2019)
12
Original Estimated Enrollment  ICMJE
 (submitted: December 6, 2017)
10
Estimated Study Completion Date  ICMJE September 30, 2026
Estimated Primary Completion Date July 8, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male, aged 18 to 75 years at the time of screening.
  • Established severe hemophilia A (FVIII:C <1%, measured following >=5 days without FVIII treatment) and/or documented intron 1 inversion or intron 22 inversion mutation in the F8 gene, consistent with severe hemophilia A , and documented evidence of >=3 hemorrhages over the previous 12 months requiring treatment with exogenous FVIII or use of FVIII prophylaxis because of history of frequent bleeding episodes.
  • History of greater than (>) 150 exposure days to exogenously administered FVIII concentrates or cryoprecipitate.
  • Sexually active men must agree to use barrier contraception (combination of a condom and spermicide) or limit sexual intercourse to post-menopausal, surgically sterilized, or contraception-practicing partners for a minimum of 6 months after administration of BAX 888, or until BAX 888 genomes are no longer detected in the semen, whichever is sooner.
  • Participant is willing and able to comply with the requirements of the protocol, including provision of semen samples, maintenance of a diary of bleeding episodes and FVIII protein use.
  • Signed informed consent.

Exclusion Criteria:

  • Bleeding disorder(s) other than hemophilia A.
  • Personal laboratory evidence of having developed inhibitors to FVIII protein at any time (>=0.6 Bethesda units [BU] on any single test).
  • Documented prior allergic reaction to any FVIII product.
  • Anti-Adeno-associated virus, serotype 8 (AAV8) neutralizing antibody titer >=1:5. Participants whose laboratory assessments are less than or equal to (<=) 1:10 may be re-tested within the same screening window and, if eligibility criterion is met on retest, may be enrolled after confirmation by the Sponsor Medical Monitor.
  • Known hypersensitivity to prednisolone or prednisone, or to any of the excipients.
  • Having a disease in which treatment with prednisolone or prednisone is not tolerated (including but not limited to osteoporosis with vertebral fractures, difficult to control hypertension, and difficult to control diabetes).
  • Evidence of markers of potential underlying risk for autoimmune mediated hepatic disease:

    • Anti-smooth muscle antibody assay results >=40 (Inova QUANTA LiteTM Actin IgG enzyme-linked immunosorbent assay [ELISA]); values of 31 to 39 will be flagged as possibly abnormal and the Investigator and Medical Monitor will evaluate the participant for eligibility.
    • Elevated anti-liver-kidney microsomal antibody type 1 (LKM1) titers.
    • Total immunoglobulin G (IgG) >1.5*upper limit of normal (ULN).
    • Antinuclear antibody (ANA) titer >1:320; OR ANA titer >1:80 if demonstrated concurrently with alanine aminotransferase (ALT) that is >ULN.
  • Active Hepatitis virus (Hepatitis C): As indicated by detectable hepatitis C virus (HCV) ribonucleic acid (RNA) by polymerase chain reaction (PCR).
  • Hepatitis B: If surface antigen is positive.
  • Seropositive for Human Immunodeficiency Virus (HIV).
  • Receiving systemic antiviral and/or interferon therapy within 4 weeks prior to enrollment.
  • Clinically significant infections (e.g. systemic fungal infections) requiring systemic treatment.
  • Known immune disorder (including myeloma and lymphoma).
  • Concurrent chemotherapy or biological therapy for treatment of neoplastic disease or other disorders.
  • An absolute neutrophil count <1000 cells per cubic millimeter (cells/mm^3).
  • Markers of hepatic inflammation or cirrhosis as evidenced by 1 or more of the following:

    • Platelet count of <150,000/microliter (mcL).
    • Serum albumin level is below the central laboratory's lower limit of normal and FibroSURE is >=0.48 (i.e., Metavir staging of F2 or greater). Of note, in participants with a known history of Gilbert's syndrome, a Fibrotest cannot be used for fibrosis testing.
    • Total bilirubin >1.5*ULN and direct bilirubin >=0.5 milligram per deciliter (mg/dL).
    • ALT or aspartate aminotransferase (AST) >1.0*ULN.
    • Alkaline phosphatase (AP) >2.0*ULN.
    • History of liver biopsy indicating moderate or severe fibrosis (Metavir staging of F2 or greater).
    • History of ascites, varices, variceal hemorrhage, or hepatic encephalopathy.
    • Any findings on screening ultrasound that would preclude the safe use of AAV gene therapy.
  • Prothrombin time (PT) international normalized ratio (INR) >=1.4.
  • Serum creatinine >1.5 mg/dL.
  • Urine protein >30 mg/dL or >0.5 gram per day (g/day).
  • Body mass index >38.
  • Major surgery or an orthopedic surgical procedure planned within 6 months after enrollment.
  • Acute or chronic disease that, in the opinion of the investigator, would adversely affect participant safety or compliance or interpretation of study results.
  • Received an AAV vector previously or any other gene transfer agent in the previous 12 months prior to Study Day 0.
  • Received an investigational intervention or participated in another clinical trial within 4 weeks prior to enrollment or within 5 half-lives of the investigational drug administration, whichever is longer.
  • Significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, congestive heart failure, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina) or significant pulmonary disease (including obstructive pulmonary disease).
  • Recent history of psychiatric illness or cognitive dysfunction (including drug or alcohol abuse) that in the opinion of the investigator, is likely to impair participants ability to comply with protocol mandated procedures.
  • Participant is a family member or employee of the investigator.
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Austria,   France,   Hungary,   Spain,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03370172
Other Study ID Numbers  ICMJE 201501
2015-005576-22 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Plan Description: Takeda does not provide access to Individual Participant Data when a study is in a very limited (small) study population due to participant privacy concerns such as potential reidentification of study participants.
Current Responsible Party Takeda ( Baxalta now part of Shire )
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Baxalta now part of Shire
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE
  • Baxalta Innovations GmbH, now part of Shire
  • Takeda Development Center Americas, Inc.
Investigators  ICMJE
Study Director: Study Director Shire
PRS Account Takeda
Verification Date November 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP